200 related articles for article (PubMed ID: 37010134)
1. Development of an Amorphous Solid Dispersion Formulation for Mitigating Mechanical Instability of Crystalline Form and Improving Bioavailability for Early Phase Clinical Studies.
Chiang CW; Lubach JW; Chen T; Chin S; Ly J; Zhang W; Hou HH; Nagapudi K
Mol Pharm; 2023 May; 20(5):2452-2464. PubMed ID: 37010134
[TBL] [Abstract][Full Text] [Related]
2. Exploration of supersaturable lacidipine ternary amorphous solid dispersion for enhanced dissolution and in vivo absorption.
Guan J; Jin L; Liu Q; Xu H; Wu H; Zhang X; Mao S
Eur J Pharm Sci; 2019 Nov; 139():105043. PubMed ID: 31415903
[TBL] [Abstract][Full Text] [Related]
3. Pharmaceutical development of an amorphous solid dispersion formulation of elacridar hydrochloride for proof-of-concept clinical studies.
Sawicki E; Schellens JH; Beijnen JH; Nuijen B
Drug Dev Ind Pharm; 2017 Apr; 43(4):584-594. PubMed ID: 28010129
[TBL] [Abstract][Full Text] [Related]
4. Ternary Amorphous Solid Dispersions Containing a High-Viscosity Polymer and Mesoporous Silica Enhance Dissolution Performance†.
Hanada M; Jermain SV; Thompson SA; Furuta H; Fukuda M; Williams RO
Mol Pharm; 2021 Jan; 18(1):198-213. PubMed ID: 33291881
[TBL] [Abstract][Full Text] [Related]
5. Impact of polymer type, ASD loading and polymer-drug ratio on ASD tablet disintegration and drug release.
Zhang W; Noland R; Chin S; Petkovic M; Zuniga R; Santarra B; Conklin B; Hou HH; Nagapudi K; Gruenhagen JA; Yehl P; Chen T
Int J Pharm; 2021 Jan; 592():120087. PubMed ID: 33189812
[TBL] [Abstract][Full Text] [Related]
6. Comparative Evaluation of Particle Size Reduction, Salt Formation, and Amorphous Formulation on the Biopharmaceutical Performance of a Weak Base Drug Candidate.
Zhang W; Jia W; Weitz BW; Ma F; Chen Y; Chiang PC; Hou HH; Nagapudi K
Mol Pharm; 2023 Nov; 20(11):5888-5900. PubMed ID: 37792707
[TBL] [Abstract][Full Text] [Related]
7. Efficient development of sorafenib tablets with improved oral bioavailability enabled by coprecipitated amorphous solid dispersion.
Song S; Wang C; Wang S; Siegel RA; Sun CC
Int J Pharm; 2021 Dec; 610():121216. PubMed ID: 34688849
[TBL] [Abstract][Full Text] [Related]
8. Formulation performance and processability window for manufacturing a dual-polymer amorphous solid dispersion via hot-melt extrusion and strand pelletization.
Hörmann TR; Jäger N; Funke A; Mürb RK; Khinast JG; Paudel A
Int J Pharm; 2018 Dec; 553(1-2):408-421. PubMed ID: 30326284
[TBL] [Abstract][Full Text] [Related]
9. Novel High-Drug-Loaded Amorphous Dispersion Tablets of Posaconazole;
Mudie DM; Stewart AM; Biswas N; Brodeur TJ; Shepard KB; Smith A; Morgen MM; Baumann JM; Vodak DT
Mol Pharm; 2020 Dec; 17(12):4463-4472. PubMed ID: 32835489
[TBL] [Abstract][Full Text] [Related]
10. Effects of tablet formulation and subsequent film coating on the supersaturated dissolution behavior of amorphous solid dispersions.
Sakai T; Hirai D; Kimura SI; Iwao Y; Itai S
Int J Pharm; 2018 Apr; 540(1-2):171-177. PubMed ID: 29447848
[TBL] [Abstract][Full Text] [Related]
11. Investigation into the Solid-State Properties and Dissolution Profile of Spray-Dried Ternary Amorphous Solid Dispersions: A Rational Step toward the Design and Development of a Multicomponent Amorphous System.
Baghel S; Cathcart H; O'Reilly NJ
Mol Pharm; 2018 Sep; 15(9):3796-3812. PubMed ID: 30020788
[TBL] [Abstract][Full Text] [Related]
12. Oral bioavailability enhancement of β-lapachone, a poorly soluble fast crystallizer, by cocrystal, amorphous solid dispersion, and crystalline solid dispersion.
Liu C; Liu Z; Chen Y; Chen Z; Chen H; Pui Y; Qian F
Eur J Pharm Biopharm; 2018 Mar; 124():73-81. PubMed ID: 29305142
[TBL] [Abstract][Full Text] [Related]
13. The impact of diluents on the compaction, dissolution, and physical stability of amorphous solid dispersion tablets.
Yu D; Hoag SW
Int J Pharm; 2024 Apr; 654():123924. PubMed ID: 38395318
[TBL] [Abstract][Full Text] [Related]
14. Formulating Amorphous Solid Dispersions: Impact of Inorganic Salts on Drug Release from Tablets Containing Itraconazole-HPMC Extrudate.
Takano R; Maurer R; Jacob L; Stowasser F; Stillhart C; Page S
Mol Pharm; 2020 Aug; 17(8):2768-2778. PubMed ID: 31794228
[TBL] [Abstract][Full Text] [Related]
15. Molecular-Level Examination of Amorphous Solid Dispersion Dissolution.
Faiz Afzal MA; Lehmkemper K; Sobich E; Hughes TF; Giesen DJ; Zhang T; Krauter CM; Winget P; Degenhardt M; Kyeremateng SO; Browning AR; Shelley JC
Mol Pharm; 2021 Nov; 18(11):3999-4014. PubMed ID: 34570503
[TBL] [Abstract][Full Text] [Related]
16. Hot Melt Extrusion: Development of an Amorphous Solid Dispersion for an Insoluble Drug from Mini-scale to Clinical Scale.
Agrawal AM; Dudhedia MS; Zimny E
AAPS PharmSciTech; 2016 Feb; 17(1):133-47. PubMed ID: 26729533
[TBL] [Abstract][Full Text] [Related]
17. The Effect of Inorganic Salt on Disintegration of Tablets with High Loading of Amorphous Solid Dispersion Containing Copovidone.
Xi H; Ren J; Novak JM; Kemp E; Johnson G; Klinzing G; Johnson MA; Xu W
Pharm Res; 2020 Mar; 37(4):70. PubMed ID: 32185516
[TBL] [Abstract][Full Text] [Related]
18. Characterizing and Exploring the Differences in Dissolution and Stability Between Crystalline Solid Dispersion and Amorphous Solid Dispersion.
Wang X; Zhang L; Ma D; Tang X; Zhang Y; Yin T; Gou J; Wang Y; He H
AAPS PharmSciTech; 2020 Sep; 21(7):262. PubMed ID: 32975680
[TBL] [Abstract][Full Text] [Related]
19. Amorphous solid dispersion of nisoldipine by solvent evaporation technique: preparation, characterization, in vitro, in vivo evaluation, and scale up feasibility study.
Chavan RB; Lodagekar A; Yadav B; Shastri NR
Drug Deliv Transl Res; 2020 Aug; 10(4):903-918. PubMed ID: 32378174
[TBL] [Abstract][Full Text] [Related]
20. Amorphous solid dispersion with increased gastric solubility in tandem with oral disintegrating tablets: a successful approach to improve the bioavailability of atorvastatin.
Salmani JM; Lv H; Asghar S; Zhou J
Pharm Dev Technol; 2015 Jun; 20(4):465-72. PubMed ID: 24490758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
